AblationforCardiacArrhythmias near Valhalla, NY

Biography: Michael B. Collins, MD is an Interventional Cardiologist at Columbia Interventional Cardiovascular Care, the Associate Director of the Cardiovascular Catheterization Lab at Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Collins specializes in complex percutaneous coronary interventions. Dr. Collins received his medical degree in 1975 from Yale University School of Medicine, New Haven, Connecticut.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Tamim Nazif, MD is the Director of Clinical Research for Columbia Interventional Cardiovascular Care,Director of the Interventional Cardiology Fellowship Program, and an associate professor in medicine at Columbia University Irving Medical Center. Dr. Nazif specializes in interventional cardiology and the treatment of heart valve disease. Dr. Nazif attended Columbia University College of Physicians and Surgeons, did his residency at University of California, San Francisco Department of Medicine, San Francisco, CA, and his fellowship in interventional cardiology and Structural Heart Disease at Columbia University Irving Medical Center.

Biography: Jeffrey W. Moses, MD, is a renowned interventional cardiologist and Professor of Medicine at Columbia University Medical Center. Dr. Moses serves as the Director of Interventional Cardiovascular Therapeutics at Columbia Interventional Cardiovascular Care and the Director of Advanced Cardiac Interventions at St Francis Hospital and Heart Center in Roslyn, NY.With a track record of over 18,000 interventional procedures, Dr. Moses is an accomplished researcher. He has served as a lead investigator for numerous national and international clinical studies and authored over 600 publications, many focusing on the effectiveness and safety of coronary stent placement. Notably, his pivotal role in a 2002 clinical trial resulted in the first U.S. FDA approval of a drug-coated stent, now widely used in American interventional procedures.Dr. Moses contributed to the Executive Committee of the PARTNER trial, which introduced the first transcatheter aortic valve for clinical use in the U.S. A pioneer in various approaches, including minimally invasive surgery, angioplasty, gene therapy, and novel imaging technologies, he extends the application of interventional cardiovascular procedures. He is a fellow in multiple professional societies and serves on the editorial board as a reviewer for numerous peer-reviewed journals.Dr. Moses serves on the Board of the Cardiovascular Research Foundation (CRF); and continues to make formidable contributions in the areas of clinical research and educational activities in interventional vascular therapy.Before his tenure at Columbia, Dr. Moses held a professorship in Clinical Medicine at New York University School of Medicine. He also played key roles at The New York Hospital (now NewYork-Presbyterian), where he served as the Associate Director of the Adult Cardiac Catheterization Laboratory and Director of Clinical Electrophysiology.Dr. Moses completed medical school at the University of Pennsylvania School of Medicine and his internship, residency, and fellowship in Cardiology at the Presbyterian University of Pennsylvania Medical Center.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. Vishal Kapur, MD is a Cardiology Specialist who practices in New York, NY. He is 48 years old and has been practicing for 24 years. Dr. Vishal Kapur, MD is affiliated with Mount Sinai Hospital and Mount Sinai Morningside.

Biography: Dr. Prakash Krishnan, MD is an Interventional Cardiology Specialist who practices in New York, NY. He is 57 years old and has been practicing for 28 years. Dr. Prakash Krishnan, MD is affiliated with Mount Sinai Hospital and Mount Sinai Morningside.

Biography: Dr. S. Chiu Wong is a Professor of Medicine of the Greenberg Division of Cardiology in the Department of Medicine of the Weill Medical College of Cornell University. He is the Director of Cardiac Catheterization laboratories at the NewYork-Presbyterian/Weill Cornell Medical Center.Dr. Wong graduated Summa Cum Laude from Columbia College in May 1980 and received his Doctor of Medicine degree from Columbia University, College of Physicians and Surgeons in May 1984. Following his medical internship, residency, and clinical cardiology training at St. Luke's/Roosevelt Medical Center in New York City, he spent one additional stent fellowship year in 1991 under the tutorage of Dr. Richard Schatz at Scripps's Clinic and Research Foundation in La Jolla, California. He is board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology.After his medical training, Dr. Wong joined the Cardiology Research Foundation at the Washington Hospital in 1992 and was appointed as Director of Coronary Stent Program in 1993. In 1995, Dr. Wong spearheaded a new cardiac catheterization program at the New York Hospital Medical Center of Queens where he assumed the directorship of coronary interventions. In October 1999, Dr. Wong was recruited to the New York Presbyterian Hospital - Cornell Campus as Director of Cardiac Catheterization Laboratories.Dr. Wong has published extensively in the field of interventional cardiology with special focus on new device angioplasty, saphenous vein graft intervention, cardiogenic shock, and drug eluting stent. His current clinical research interests include novel drug eluting stent designs, access site and PFO closure devices, percutaneous valve repair, and application of stem cell technology in the treatment of myocardial ischemia. In the past five years, Dr. Wong and his colleagues had participated in multiple US pivotal trials that led to the FDA approval of both drug eluting stents for the treatment of symptomatic obstructive coronary artery disease. Dr. Wong has recently served as the national principal investigation in the ECLIPSE trial which evaluated the safety and efficacy of an extra-vascular bio-degradable access site closure device in patients undergoing coronary or peripheral diagnostic/interventional procedures compare to the standard treatment of manual compression.Other exciting areas of ongoing research include percutaneous treatment valvular disease states including mitral regurgitation and aortic stenosis, assessment of novel pharmacologic agents to enhance safety of angioplasty procedures.His clinical research activities have been published in Journal of American College of Cardiology, American Journal of Cardiology, American heart Journal and he has presented his findings at numerous national and international meetings including American Heart Association, American College of Cardiology, Transcatheter Therapeutics, Summer in Seattle, Taiwan Society of Cardiology and Asia Pacific Cardiology Congress. He is recruited to serve as member of the Scientific Advisory Board of multiple major US medical device companies.